SCHEMBL26686734

SCHEMBL26686734

Nc1n[nH]c2c(Cl)cc(-c3ccnc4[nH]c(CCN5CCOCC5)cc34)cc12

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CCNK O75909 3/20 0.44
▸ CDK12 Q9NYV4 3/20 0.44
▸ CAMKK2 Q96RR4 7/20 0.41
▸ MAPK8 P45983 6/20 0.41
▸ CHUK O15111 5/20 0.41
▸ INSR P06213 4/20 0.41
▸ JAK2 O60674 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ DRD4 P21917 1/20 0.39
▸ DRD3 P35462 1/20 0.39
▸ AURKA O14965 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ PIK3C3 Q8NEB9 1/20 0.38
▸ NEK1 Q96PY6 1/20 0.38
▸ CCNT1 O60563 2/20 0.37
▸ CDK9 P50750 2/20 0.37
▸ TBK1 Q9UHD2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26686752 0.91 CCNK (0.52) CCNKCDK12CAMKK2MAPK8CHUK
SCHEMBL31240468 0.91 CCNK (0.52) CCNKCDK12CAMKK2MAPK8CHUK
SCHEMBL26686058 0.84 JAK2 (0.53) CCNKCDK12CAMKK2MAPK8CHUK
SCHEMBL30633347 0.83 CCNK (0.40) CCNKCDK12CAMKK2MAPK8CHUK
SCHEMBL26686212 0.83 CCNK (0.40) CCNKCDK12CAMKK2MAPK8CHUK
SCHEMBL26686396 0.83 CCNK (0.41) CCNKCDK12CAMKK2MAPK8CHUK
SCHEMBL31240470 0.82 CAMKK2 (0.55) CAMKK2MAPK8CHUKINSRJAK2
SCHEMBL31240591 0.80 TBK1 (0.53) CAMKK2MAPK8CHUKINSRJAK2
SCHEMBL26686172 0.79 JAK2 (0.51) CCNKCDK12CAMKK2MAPK8CHUK
SCHEMBL26686635 0.78 CCNK (0.48) CCNKCDK12DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP claimed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO claimed
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP disclosed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN disclosed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB CCNK 222/4885CDK12 171/4885CAMKK2 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback